Replies to post #213272 on Biotech Values

[jbog]

The NEJM had the full report this morning on Canakinumab this morning.

Their editorial basically said that while treating inflammation looks very interesting to explore, at $100k to $200K per year, it isn't going to the masses.

[DewDiligence]

NVS’ own PR on CANTOS study of Ilaris (a/k/a ACZ885/canakinumab):

https://www.novartis.com/news/media-releases/novartis-phase-iii-cantos-study-demonstrates-targeting-inflammation-acz885

Note: CANTOS top-line results were reported in June (#msg-132398529), but the full dataset was presented for the first time this weekend.

[north40000]

Doubt if it is "for the first time." How long did clinical trial of NVS last vis a vis Marine(FDA-approved indication), Anchor and 8000+ patient Reduce-It trials of Amarin for Vascepa? I have been prescribed Vascepa, off-label, since April 1, 2013. My latest EPA/AA ratio is 1.7. I have read not read NEJM yet---does NVS report comparable ratios for anti-inflammatory effect?

BTW, I co-pay $9/month for my off-label prescription of Vascepa.

IDMC recommended the R-I trial continue, as planned, 2 weeks ago.